Jeffrey L. Wade - 28 Feb 2024 Form 4 Insider Report for LEXICON PHARMACEUTICALS, INC. (LXRX)

Role
President and CFO
Signature
/s/ Jeffrey L. Wade
Issuer symbol
LXRX
Transactions as of
28 Feb 2024
Net transactions value
-$98,750
Form type
4
Filing time
29 Feb 2024, 16:32:30 UTC
Previous filing
12 Feb 2024
Next filing
08 Jul 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LXRX Common Stock Options Exercise +11,177 +4.2% 275,518 28 Feb 2024 Direct F1
transaction LXRX Common Stock Options Exercise +37,274 +14% 312,792 28 Feb 2024 Direct F1
transaction LXRX Common Stock Options Exercise +49,113 +16% 361,905 28 Feb 2024 Direct F1
transaction LXRX Common Stock Tax liability $98,750 -37,691 -10% $2.62 324,214 28 Feb 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LXRX Restricted Stock Units Options Exercise -11,177 -100% 0 28 Feb 2024 Common Stock 11,177 Direct F1, F3
transaction LXRX Restricted Stock Units Options Exercise -37,274 -50% 37,273 28 Feb 2024 Common Stock 37,274 Direct F1, F3
transaction LXRX Restricted Stock Units Options Exercise -49,113 -33% 98,227 28 Feb 2024 Common Stock 49,113 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of common stock.
F2 Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto.
F3 Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant.